Raised sputum extracellular DNA confers lung function impairment and poor symptom control in an exacerbation-susceptible phenotype of neutrophilic asthma

Mustafa Abdo1, Mohib Uddin2, Torsten Goldmann3, Sebastian Marwitz3, Thomas Bahmer4, Olaf Holz5, Anne-Marie Kirsten6, Frederik Trinkmann7,8, Erika von Mutius9, Matthias Kopp10,11, Gesine Hansen12, Klaus F. Rabe1, Henrik Watz6 and Frauke Pedersen1,6* on behalf of the ALLIANCE study group

Abstract

Background: Extracellular DNA (e-DNA) and neutrophil extracellular traps (NETs) are linked to asthmatics airway inflammation. However, data demonstrating the characterization of airway inflammation associated with excessive e-DNA production and its impact on asthma outcomes are limited.

Objective: To characterize the airway inflammation associated with excessive e-DNA production and its association with asthma control, severe exacerbations and pulmonary function, particularly, air trapping and small airway dysfunction.

Methods: We measured e-DNA concentrations in induced sputum from 134 asthma patients and 28 healthy controls. We studied the correlation of e-DNA concentrations with sputum neutrophils, eosinophils and macrophages and the fractional exhaled nitric oxide (FeNO). Lung function was evaluated using spirometry, body plethysmography, impulse oscillometry and inert gas multiple breath washout. We stratified patients with asthma into low-DNA and high-DNA to compare lung function impairments and asthma outcomes.

Results: Patients with severe asthma had higher e-DNA concentration (54.2 ± 42.4 ng/µl) than patients with mild-moderate asthma (41.0 ± 44.1 ng/µl) or healthy controls (26.1 ± 16.5 ng/µl), (all p values < 0.05). E-DNA concentrations correlated directly with sputum neutrophils (R= 0.49, p < 0.0001) and negatively with sputum macrophages (R= −0.36, p < 0.0001), but neither with sputum eosinophils (R= 0.10, p = 0.26), nor with FeNO (R= −0.10, p = 0.22). We found that 29% of asthma patients (n = 39) had high e-DNA concentrations above the upper 95th percentile value in healthy controls (55.6 ng /µl). High-DNA was associated with broad lung function impairments including: airflow obstruction of the large (FEV1) and small airways (FEF50%, FEF25–75), increased air trapping (RV, RV/TLC), increased small airway resistance (R5‑20, sReff), decreased lung elasticity (X5Hz) and increased ventilation heterogeneity (LCI), (all P values < 0.05). We also found that high e-DNA was associated with nearly three-fold greater risk of severe...
exacerbations (OR 2.93 [95% CI 1.2–7.5]; p = 0.012), worse asthma control test (p = 0.03), worse asthma control questionnaire scores (p = 0.01) and higher doses of inhaled corticosteroids (p = 0.026).

**Conclusion:** Increased production of extracellular DNA in the airway characterizes a subset of neutrophilic asthma patients who have broad lung function impairments, poor symptom control and increased risk of severe exacerbations.

**Keywords:** Extracellular DNA, Neutrophil extracellular traps, Neutrophilic asthma, Asthma outcomes

**Background**

Asthma is a heterogeneous disease that comprises several clinical phenotypes [1]. A considerable proportion of asthma patients are thought to have the neutrophilic phenotype [2] which is characterized by high sputum neutrophil counts and is linked to asthma severity [3], frequent exacerbations [4], and steroid resistance [5]. Unravelling the role of neutrophils in the pathophysiology of asthma is still ongoing and has the potential to reveal novel molecular mechanisms and druggable targets. Recent studies have begun to reveal the potential pro-inflammatory role of extracellular DNA (e-DNA) released by activated airway neutrophils in asthma [6, 7]. Extracellular DNA forms web-like scaffolds in combination with histones and neutrophil granular proteins, such as myeloperoxidase (MPO) and neutrophil elastase (NE), called the neutrophil extracellular traps (NETs) [8]. Although NETs are important components of the antimicrobial innate immunity, aberrant NETs production might be harmful to the airway tissue through the excessive release of the histotoxic components of NETs, including proteases (MPO, NE) into the extracellular surroundings. This can promote airway mucosal inflammation, induce epithelial cell death and contribute to airway mucus hypersecretion, causing NETopathic airway inflammation [9, 10]. Recent work by Lachowicz-Scroggins and colleagues showed that high sputum e-DNA concentration in asthma patients was accompanied by raised sputum neutrophils and was associated with activation of innate immune responses and elevated sputum cytokines (e.g. IL-1β) [6].

Taken together, excessive e-DNA formation and the subsequent NETopathic inflammation point to a potential pathobiological role in asthmatic inflammation, but insights into broader asthma outcomes are limited. In particular, there is a lack of data demonstrating the interplay between high e-DNA with asthma control and pulmonary function, particularly, lung function measures beyond airflow obstruction, such as air trapping and small airway dysfunction. Furthermore, there are still uncertainties about the characterization of airway inflammation associated with high e-DNA production in asthma, as airway eosinophils might also contribute to e-DNA production [11].

Therefore, we evaluated the association of sputum e-DNA concentration with differential sputum cells concentrations, pulmonary function, symptom control and the frequency of severe exacerbations in asthma patients.

**Methods**

**Study design**

Eligible subjects were adults with asthma and healthy controls who were recruited to the multicenter prospective longitudinal All Age Asthma Cohort (ALLANCE), a cohort of pediatric and adult patients with asthma in Germany, initiated by the German Centre for Lung Research (DZL). The study was approved by a local Ethics Committee at the Medical School of Lübeck (Az.21-215) and is registered at clinicaltrials.gov (adult arm: NCT02419274). All subjects provided written informed consent prior to enrollment. Detailed information regarding recruitment, inclusion and exclusion criteria was described previously [12]. This study was a cross-sectional analysis on the baseline data. Sputum specimens were available for 142 asthma patients and 34 healthy controls. Six healthy controls and eight asthma patients were excluded due to insufficient sputum quality. Eventually, 162 subjects were included in our data analysis. The subjects had to have stable disease without acute exacerbations or respiratory tract infections within four weeks prior to study visit. Asthma patients with current or former smoking history were also included. Healthy controls were never-smokers, had normal spirometry and no history of lung diseases.

**Sputum preparation and extracellular DNA quantification**

Sputum was induced and processed according to standardized procedures [13]. Briefly, patients inhaled hypertonic nebulized saline (3–4–5%, each 7 min) for a total inhalation time of 21 min. Induction was discontinued if FEV1 fell by more than 20% as compared with baseline. Sputum plugs were selected within one hour after induction. The sputum plugs of all inhalation periods were pooled, weighted and incubated with four volumes of 0.1% dithiothreitol (DTT, Sputolysin®, Calbiochem, Bad Soden, Germany) for 15 min at room temperature. Thereafter, 2 volumes of phosphate buffered saline (PBS) were added and cell suspension was filtered through a 70 µm
cell strainer. Subsequently, cell suspension was centrifuged (600 g, 4 °C, 10 min). Supernatants for e-DNA quantification were frozen at ~80 °C. The remaining cell pellets were resuspended in PBS. Total cell counts and viability were determined by haemacytometer and trypan blue (Sigma, Deisenhofen, Germany) staining. Cytospins were prepared and differential cell counts analyzed as previously described [13]. Sputum supernatant samples for extracellular-DNA quantification were thawed and mixed thoroughly. 1 µl of supernatant was transferred to the measurement pedestal of the NanoDrop 2000 spectrophotometer (Thermo Fischer Scientific, Inc., Waltham, MA). Extracellular DNA concentration was measured by determining the absorbance at 260 nm. All measurements were performed in duplicate according to manufacturer’s manual (https://assets.thermofisher.com/TFS-Assets/CAD/manuals/NanoDrop-2000-User-Manual-EN.pdf). A mixture of four volumes of 0.1% DTT and 3 parts PBS was used as negative control [14].

We classified patients with asthma into high-DNA and low-DNA to study the association of sputum e-DNA with sputum cell concentrations, pulmonary function and asthma outcomes. Further, we compared e-DNA concentrations between patients based on their sputum inflammatory cellular patterns i.e. (eosinophils ≥ 2%, eosinophils ≥ 3%, neutrophils ≥ 40% and neutrophils ≥ 65%) [2, 15].

Asthma severity and symptom control
We defined severe asthma based on European Respiratory Society/American Thoracic Society guidelines [16]. Further, asthma control was assessed by the asthma control test (ACT), asthma control questionnaire (ACQ5) and the annualized number of severe exacerbations 12 months prior to study visit, defined as a burst of systemic corticosteroids for ≥ 3 days [16].

Lung physiology characteristics
We performed spirometry, body plethysmography, impulse oscillometry (IOS) and inert gas multiple breath washout (MBW) in accordance to current ERS recommendations [17–20]. Measures of airflow obstruction were the forced expiratory volume in the first second (FEV₁) and its ratio to the forced vital capacity (FVC). Measures and indirect markers of small airway function were: mean forced expiratory flow at 50% and between 25 and 75% of the forced vital capacity (FEF50%, FEF25–75%) from forced spirometry, specific effective airway resistance (sReff), residual lung volume (RV), and ratio of RV to total lung capacity (RV/TLC) from body plethysmography, the small airway resistance (R5Hz–20 Hz) and lung reactance at 5 Hz (XHz) from IOS, and lung clear ance index (LCI) measured by MBW.

Statistical analysis
We used the unpaired t-test, Wilcoxon rank test or Fisher exact test to determine the significance of differences in clinical variables between the study groups. We used Fisher’s exact test to determine the odds ratio of severe exacerbation in the study groups. Spearman’s rank correlation was used to test for statistical dependence between two variables. Statistical analyses were performed using R (version 3.6.2; R Foundation, Vienna, Austria). An alpha error of less than 5% was considered statistically significant.

Results
We included 70 patients with mild to moderate asthma, 64 patients with severe asthma and 28 healthy controls. Compared to healthy controls, patients with asthma were older, heavier and had increased neutrophil and eosinophil concentrations in blood and sputum. Detailed clinical characteristics are given in Table 1. Furthermore, asthma patients had significantly increased sputum e-DNA concentrations compared to healthy subjects (47.3 ± 43.6 vs 26.1 ± 16.5 ng/µl, p = 0.002). The concentration of sputum e-DNA was also elevated in severe asthma compared to mild-moderate asthma patients (Fig. 1).

Table 1 Characteristics of healthy subjects and patients with asthma

| Characteristic | Healthy (n = 28) | Asthma (n = 134) | P-value |
|---------------|-----------------|-----------------|---------|
| Age, years    | 41.4 ± 18       | 52.3 ± 12       | 0.002   |
| Sex, % male   | 53              | 47              | 0.54    |
| BMI, kg/m²    | 25.2 ± 3.8      | 27.6 ± 5.1      | 0.016   |
| Smoking history | 0              | 23              | 0.005   |
| Current smokers, % | 0           | 9               | <0.001  |
| Severe asthma, % | –           | 48              | –       |
| FEV₁, %       | 102             | 83.5            | <0.001  |
| FVC, %        | 110             | 105             | 0.67    |
| FEV₁/FVC, %   | 77.5            | 65.1            | <0.001  |
| Blood cell counts, 10⁹/µl |               |                 |         |
| Eosinophils   | 145 (90–182)    | 240 (140–450)   | <0.001  |
| Neutrophils   | 2770 (2435–3452)| 4210 (3370–5960)| <0.001  |
| Sputum cell counts, %* |        |                 |         |
| Eosinophils   | 0.1 (0.0–0.30)  | 1.5 (0.4–7.0)   | <0.001  |
| Neutrophils   | 25.5 (14–51)    | 53.3 (32–71)    | 0.008   |
| Macrophages   | 67.2 (44–81)    | 31 (15–53)      | 0.003   |

Data are reported in mean ± SD or median (interquartile range)

BMI body mass index, FEV₁ predicted forced expiratory volume in the 1 s, FVC forced vital capacity, Smoking history: current or former smokers with smoking history ≥ 10 pack years

* Sputum cell counts percentage of non-squamous cells
In healthy controls, we identified a cutoff value (55.6 ng/µl) at the 95th percentile to be the upper limit of normal for sputum e-DNA concentration. Accordingly, 29% of asthma patients (n = 39) had e-DNA concentrations more than 55.6 ng/µl and were stratified as high-eDNA, remaining patients (n = 95) were stratified as low-eDNA. Mean e-DNA concentrations were 94.7 ± 52 and 27.8 ± 16 ng/µl in high and low-eDNA patients, respectively. Clinical features of high-eDNA and low-eDNA patients are represented in Table 2. Comparing high-DNA to low-DNA patients, we observed no statistically significant differences between both groups regarding demographics features, BMI or smoking habits (Table 2). A greater proportion of high-eDNA patients were found to have regular oral corticosteroids (OCS) with higher doses of both OCS and inhaled corticosteroids (ICS). However, only the difference in ICS dose was statistically significant (p = 0.026).

While patients with high-eDNA concentrations had markedly heightened sputum neutrophils (65%) compared to low-eDNA patients (48%), there were no significant differences in type 2 (T2) markers i.e. blood and sputum eosinophils and FeNO between both groups. However, interestingly, enumeration of sputum macrophage levels in patients with high-DNA showed significantly lower percentage of airway macrophages relative to low-DNA patients, (19% vs 37%; p = 0.002), respectively, suggesting a potential reciprocal relationship between sputum neutrophils and these phagocytes.

Further, the mean concentration of sputum e-DNA in patients with eosinophilic asthma was similar to the e-DNA concentration in patients with non-eosinophilic asthma, both as defined by sputum eosinophils ≥ 2% (46.2 vs 41.3 ng/µl, p = 0.35) and sputum eosinophils ≥ 3% (43.6 vs 43.1 ng/µl, p = 0.97). By contrast, neutrophilic asthma patients had significantly higher e-DNA concentration compared to non-neutrophilic asthma patients, where neutrophilic asthma was defined as both sputum neutrophils ≥40%, (52.6 vs 36.3 ng/µl, p < 0.01) and sputum neutrophils ≥65% (63.28 vs 39.3 ng/µl, p < 0.001). Additionally, e-DNA concentrations correlated directly with sputum neutrophils counts (R = 0.49), p < 0.0001 and negatively with the percentage of sputum macrophages to sputum non-squamous cells (R = – 0.36, p < 0.0001), (Fig. 2a, f), but neither with sputum eosinophils nor with FeNO (Fig. 2c–e, g). The sputum analysis indicated good cell yield and viability in both groups (Table 2).

Furthermore, we noticed that high-eDNA patients had worse lung function with airflow obstruction of the large (FEV1) and small airways (FEF50%, FEF25–75%), in addition to increased air trapping (RV, RV/TLC), increased small airway resistance (R5-20, sReff), decreased lung elasticity (X5Hz), and increased ventilation heterogeneity (LCI) (Table 2). While the e-DNA concentration correlated similarly with the airflow obstruction in the large (FEV1) and small airways (FEF50%) as measured by spirometry (Table 3), it correlated even better with air trapping (RV/TLC) and ventilation heterogeneity (LCI). However, these correlations were fairly weak (Table 3).

Furthermore, we also found that most of high-eDNA patients had severe asthma (Table 2) and poor symptom control (Fig. 3a, b). Of clinical relevance, the odds of severe asthma exacerbations were nearly three-fold greater in the high e-DNA asthma cohort than in the low e-DNA asthma cohort (OR 2.93 [95% CI 1.2–7.5]; p = 0.012) and these associations were suggestive of an exacerbation-susceptible phenotype of neutrophilic asthma.

**Discussion**

Our findings indicate an upregulated extracellular DNA production in the sputum supernatants of asthma patients compared with healthy controls. They also indicate that the increase in sputum e-DNA production is associated with asthma severity. Furthermore, sputum e-DNA concentrations correlated directly with sputum neutrophil counts. By contrast, we found no significant correlations between sputum e-DNA concentrations and sputum eosinophil counts. Moreover, significantly lower levels of airway macrophages were noted in patients with high e-DNA accompanied by sputum neutrophilia compared to low-DNA patients. Heightened sputum e-DNA was associated with airflow obstruction in the proximal and distal airways, increased small airway resistance, air trapping and ventilation heterogeneity. Furthermore, heightened sputum e-DNA was associated with poor symptom control and increased risk of severe exacerbations.
exacerbations, potentially indicating an exacerbation-susceptible phenotype of neutrophilic asthma.

We observed that 64% of the high-DNA patients had severe asthma versus 41% from patients with low-DNA (\(p = 0.021\)). In the study by Lachowicz-Scroggins and colleagues, they observed that heightened sputum e-DNA was associated with multiple clinical indicators of asthma severity, however, the distribution of severe asthma patients between low and high-eDNA patients was similar in their study (61% vs 66%) [6]. This discrepancy might be explained by the different cutoff value (3.8 µg/ml) that was used to define the upper limit of normal sputum

---

### Table 2  Characteristics of patients with asthma classified by DNA concentration

| Characteristic | Low-eDNA \((n = 95)\) | High-eDNA \((n = 39)\) | P-value |
|---------------|----------------------|----------------------|---------|
| Age, years    | 52 (44–63)           | 51 (43–59)           | 0.57    |
| Sex, % male   | 49                   | 41                   | 0.44    |
| BMI, kg/m²    | 27.3 (24.0–29.0)     | 26.3 (23.8–34.4)     | 0.58    |
| Smoking history % | 20                 | 27                   | 0.37    |
| Current smokers, % | 9                 | 10                   | 1.0     |
| Severe asthma, % | 41                 | 64                   | 0.021   |
| Severe exacerbations in last 12 months, % | 49 | 74 | 0.012 |
| ICS dose, µg  | 450 (250–950)        | 500 (450–1000)       | 0.026   |
| OCS use, %    | 20                   | 33                   | 0.12    |
| OCS dose; mg  | 7.5 (5–11)           | 12 (10–15)           | 0.14    |
| Blood cell counts, \(10^7/\mu l\) | | | |
| Eosinophils   | 245 (140–477)        | 190 (135–450)        | 0.56    |
| Neutrophils   | 4035 (3302–5758)     | 4810 (3415–6135)     | 0.24    |
| Sputum cell counts | | | |
| Eosinophils, \(10^5/ml\) | 0.03 (0.01–0.14) | 0.06 (0.01–0.24) | 0.29 |
| Eosinophils, %* | 1.5 (0.4–5.1) | 2.0 (0.35–14.1) | 0.87 |
| Neutrophils, \(10^5/ml\) | 0.81 (0.31–1.83) | 2.5 (1.0–5.8) | <0.0001 |
| Neutrophils, %* | 48 (30–61) | 65 (40–77) | 0.005 |
| Macrophages, \(10^5/ml\) | 0.56 (0.36–0.93) | 0.67 (0.37–1.1) | 0.43 |
| Macrophages, %* | 37 (18–56) | 19 (11–34) | 0.002 |
| Sputum cell viability, % | 80 (71–87) | 80 (70–88) | 0.93 |
| Duration of sputum induction, min | 21 (14–21) | 21 (14–21) | 0.30 |
| FeNO, ppb     | 25 (15–46)           | 22 (11–35)           | 0.1     |
| FEV1, %       | 87 (74–99)           | 76 (59–87)           | 0.002   |
| FVC, %        | 109 (96–116)         | 104 (90–112)         | 0.06    |
| FEV1/FVC, %   | 68 (61–73)           | 62 (54–72)           | 0.059   |
| FEF50, %      | 58 (38–78)           | 37 (24–61)           | 0.004   |
| FEF25–75, (l/s) | 1.74 (1.2–2.3) | 1.19 (0.64–2.0) | 0.016 |
| R20, KPa/l/s  | 0.32 (0.27–0.38)     | 0.33 (0.28–0.41)     | 0.29    |
| RS, KPa/l/s   | 0.40 (0.35–0.50)     | 0.49 (0.38–0.62)     | 0.043   |
| RS, 20, %     | 32 (16–54)           | 51 (20–80)           | 0.058   |
| X5Hz, KPa/l/s | −0.12 (−0.18–0.09)   | −0.20 (−0.26–0.13)   | <0.001  |
| RV, %         | 118 (103–132)        | 132 (107–164)        | 0.015   |
| RV/TLC, %     | 36 (33–42)           | 41 (37–48)           | 0.012   |
| sReff, %      | 98 (75–138)          | 133 (89–189)         | 0.016   |
| LCI           | 6.1 (5.6–6.6)        | 6.9 (6.2–7.9)        | <0.001  |

Data are reported in median (interquartile range)

BMI body mass index, ICS inhaled corticosteroids, ICS dose fluticasone equivalent, OCS oral corticosteroids, FeNO fractional exhaled nitric oxide, FEV1 forced expiratory volume in first second, FVC forced vital capacity, FEF50% and FEF25–75 mean forced expiratory flow at 50% and between 25 and 75% of the forced vital capacity, R20 proximal airway resistance at 20 Hz, RS-20 small airway resistance (total lung resistance – large airway resistance), X5 lung reactance at 5 Hz, RV residual volume, TLC total lung capacity, sReff specific effective airway resistance, LCI lung clearance index from multiple breath washout

* Sputum cell counts percentage of non-squamous cells

---
Fig. 2  Spearman’s correlations between e-DNA concentrations and absolute sputum cell counts $\times 10^6$/ml (A, C and E), or sputum cell counts in percentage of sputum non-squamous cells (B, D and F) and with the fractional exhaled nitric oxide (FeNO) (parts per billion, ppb), (G).
Fig. 2 continued
e-DNA concentration which could also reflect the different e-DNA measuring techniques utilized in that study. The higher levels of sputum eDNA that we observed in more severe asthma patients are consistent with recent reports demonstrating that elevated levels of circulating NETs correlate with increasing asthma severity [7]. Furthermore, e-DNA concentrations correlated directly with sputum neutrophil counts but neither with sputum eosinophils nor with FeNO. This finding is consistent with previous findings that incriminated the activated airway neutrophils in excessive e-DNA production in asthma [6, 20]. Taken together, this implies that the major source of e-DNA in sputum is of neutrophil origin, even though also eosinophils might contribute to extracellular traps in airway mucosa of atopic asthmatics [11].

We also observed lower proportion of airway macrophages in patients with high e-DNA who had sputum neutrophilia compared to low-DNA patients. This finding is particularly interesting, because airway macrophages play a crucial role in the clearance of apoptotic neutrophils and cellular debris [21] to facilitate the resolution of inflammation. Previous studies have demonstrated defective neutrophil apoptosis and efferocytosis with an impaired phagocytic capacity of airway-derived macrophages in patients with neutrophilic airway inflammation including asthma [22–24]. It is reasonable to speculate whether a reduced number of airway macrophages observed could adversely impede phagocytic clearance to facilitate localized NET burden, potentially contributing to persistent NETopathic lung inflammation. However, a caveat with this premise is that we observed only significant lower proportion, but not absolute number, of sputum macrophages in patient with high-eDNA. Furthermore, the functional activity of airway macrophages may be more important than their cell numbers, thus, further studies are warranted to characterize the molecular mechanisms underlying the defects in macrophage functionality.

We observed that a numerically greater proportion of high-eDNA patients had regular OCS use with higher dosage. It was also noteworthy that the ICS dose was significantly higher in high-eDNA patients who also had a higher abundance of neutrophils sputum neutrophils.

### Table 3: Univariate correlations between sputum e-DNA concentrations and lung physiology characteristics

| Lung physiology characteristics | Spearman’s correlation coefficient (ρ) | P value |
|---------------------------------|---------------------------------------|---------|
| FEV1, %                         | −0.18                                 | 0.036   |
| FVC, %                          | −0.11                                 | 0.19    |
| FEV1/FVC, %                     | −0.14                                 | 0.11    |
| FEF50, %                        | −0.18                                 | 0.031   |
| FEF25–75, (l/s)                 | −0.16                                 | 0.06    |
| RS-20, %                        | 0.15                                  | 0.09    |
| X5Hz, KPa/l/s                   | −0.16                                 | 0.06    |
| RV, %                           | 0.24                                  | 0.004   |
| RV/TLC, %                       | 0.26                                  | 0.002   |
| sReff, %                        | 0.10                                  | 0.26    |
| LCI                             | 0.32                                  | <0.001  |

**FEV1** forced expiratory volume in first second, **FVC** forced vital capacity, **FEF50% and FEF25–75** mean forced expiratory flow at 50% and between 25 and 75% of the forced vital capacity, **RS-20** proximal airway resistance at 20 Hz, **RS-20 small airway resistance** (total lung resistance – large airway resistance), **X5 lung reactance** at 5 Hz, **RV** residual volume, **TLC** total lung capacity, **sReff** specific effective airway resistance, **LCI** lung clearance index from multiple breath washout.
This might indicate that the presence of neutrophilic airway inflammation and the subsequent NET formation are not suppressible by corticosteroid treatment [25, 26], or even are attributable to increased airway neutrophils under systemic corticosteroids therapy [27]. Whether the sputum-enriched e-DNA is related to higher ICS doses or reflects a distinct pathobiology of severe neutrophil asthma is currently unclear; prospective mechanistic studies may provide further insights.

Moreover, upregulated sputum e-DNA production was associated with proximal airway obstruction and small airway disease. Accordingly, we also observed increased air trapping and ventilation heterogeneity in high-eDNA patients. Our findings regarding the correlation of sputum e-DNA with airflow obstruction are consistent with previous findings from patients with chronic obstructive pulmonary disease (COPD) [28] and cystic fibrosis (CF) [29]. It has been suggested that increased e-DNA production in the airways contributes to airflow obstruction by increasing the airway secretions [30] and mucus viscoelasticity [31], and by the contribution to airway inflammation through both activated proteases [32] and the proinflammatory cytokines [6]. Corresponding to lung function impairments, in our cohort, high-eDNA concentrations were also associated with nearly a threefold increase in the risk of severe exacerbations and frequent symptoms compared to low-eDNA patients with asthma, potentially indicating an exacerbation-susceptible phenotype of neutrophilic asthma.

Furthermore, we found that e-DNA concentrations in sputum were not affected by the current smoking status or former smoking history, in line with our previous finding where we showed that NET formation was not associated with current smoking in patients with COPD [14].

**Fig. 3** The association between sputum e-DNA concentration and symptom control: high-DNA is associated with poor symptom control. *ACT* asthma control test, *ACQ* asthma control questionnaire. P-values are from Wilcoxon–Mann–Whitney-Test.
Our study has some limitations. First, we relied on extracellular DNA quantification rather than the semi-quantitative direct visualization of NETs. However, the quantification of extracellular DNA in sputum supernatants is representative and reliable method that has been validated as a surrogate marker for NETs in chronic lung diseases, including asthma [6, 14]. Second, we did not measure proteases and proinflammatory cytokines that trigger endogenous NET formation which might have supported our findings and helped understanding the mechanism of e-DNA induced airway inflammation.

In summary, we have established that the increased production of extracellular DNA in the airways characterizes a subset of neutrophilic asthma patients who have broad lung function impairments, poor symptom control with an exacerbation-susceptible phenotype. Mechanistically, we propose that both corticosteroid treatment and the impaired macrophage phagocytic capacity are potential mechanisms that might contribute to the presence of persistent neutrophilic airway inflammation and e-DNA/NET enriched microenvironment in asthma. Further studies are warranted to determine the precise mechanism of extracellular DNA in the pathophysiology of neutrophilic severe asthma.

**Abbreviations**

ACQ5: Asthma control questionnaire; ACT: Asthma control test; COPD: Chronic obstructive pulmonary disease; E-DNA: Extracellular DNA; FeNO: Fractional exhaled nitric oxide; ICS: Inhaled corticosteroid; OCS: Oral corticosteroid; NETs: Neutrophil extracellular traps.

**Acknowledgements**

We thank Regine Wieland, Petra Hundack-Winter, Margret Gleiniger, Zaklina Hinz, Susann Prange, Corinna Derwort (LungClinic Grosshansdorf, Grosshansdorf, Germany) for their excellent support in study logistics.

**Authors’ contributions**

Conception and design of the study: MA, FP and HW; sputum processing and DNA measure: FP, TG and SM; acquisition, analysis and interpretation: MA, MU, FP, HW; drafting the manuscript: MA, MU, FP; critically revises the manuscript: MA, FP, HW; DNA measure proteases and proinflammatory cytokines that determine the precise mechanism of extracellular DNA quantification rather than the semi-quantitative direct visualization of NETs. However, the quantification of extracellular DNA in sputum supernatants is representative and reliable method that has been validated as a surrogate marker for NETs in chronic lung diseases, including asthma [6, 14]. Second, we did not measure proteases and proinflammatory cytokines that trigger endogenous NET formation which might have supported our findings and helped understanding the mechanism of e-DNA induced airway inflammation.

In summary, we have established that the increased production of extracellular DNA in the airways characterizes a subset of neutrophilic asthma patients who have broad lung function impairments, poor symptom control with an exacerbation-susceptible phenotype. Mechanistically, we propose that both corticosteroid treatment and the impaired macrophage phagocytic capacity are potential mechanisms that might contribute to the presence of persistent neutrophilic airway inflammation and e-DNA/NET enriched microenvironment in asthma. Further studies are warranted to determine the precise mechanism of extracellular DNA in the pathophysiology of neutrophilic severe asthma.

**Funding**

The ALLIANCE infrastructure is provided by the participating sites of the German Centre for Lung Research (DZL) and associated study centers and hospitals. Direct costs of the ALLIANCE Cohort are being paid by project grants from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF), grant number "82DZL001A4".

**Availability of data and materials**

The datasets used during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The study is a part from the prospective longitudinal All Age Asthma Cohort (ALLIANCE). The study was approved by local ethics committee at Medical School Luebeck, Germany, and is registered at clinicaltrials.gov (pediatric arm: NCT02496468; adult arm: NCT02419274).

**Consent for publication**

Not applicable.

**Competing interests**

Mustafa Abdo reports no conflict of interest. Mohib Uddin reports no conflict of interest. Torsten Goldmann reports no conflict of interest; Sebastian Marwitz reports no conflict of interest, Thomas Bahmer reports grants from BMBF. The unrestricted research grant for the German Center for Lung Research (DZL) during the conduct of the study; personal fees from AstraZeneca, personal fees from GlaxoSmithKline, personal fees from Novartis, and personal fees from Roche, outside the submitted work. Olaf Holz reports no conflict of interest; Anne-Marie Kirsten reports no conflict of interest. Frederik Trinkmann received travel support from Actelion, Berlin Chemie, Boehringer Ingelheim, Chiesi, Novartis, Mundipharma and TEVA as well as speaker or consultation fees from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, GlaxoSmithKline, Novartis and Roche, Sanofi aventis, all outside the submitted work. Erika von Mutius reports personal fees from Pharmaventures, personal fees from OM Pharma S. A., personal fees from Springer-Verlag GmbH, personal fees from Elsevier GmbH and Elsevier Ltd., personal fees from Peptinnovate Ltd., personal fees from Turun Yliopisto, personal fees from Elsevier Ltd., personal fees from Helsingin Yliopisto, personal fees from European Respiratory Society, personal fees from Deutsche Pharmazeutische Gesellschaft e. V., personal fees from Massachusetts Medical Society, personal fees from Chinese University of Hongkong, personal fees from European Commission, personal fees from Boehringer Ingelheim International GmbH, personal fees from Univeristet Utrecht, Faculitey Diergeneeskunde, personal fees from Universitat Salzburg, personal fees from Georg Thieme Verlag, personal fees from Japanese Society of Pediatric Allergy and Clinical Immunology (USPACI), outside the submitted work; In addition, Dr. von Mutius has a patent LU101064 - Barn dust extract for the prevention and treatment of diseases pending, a patent EP2361632: Specific environmental bacteria for the protection from and/or the treatment of allergic; chronic inflammatory and/or autoimmune disorders with royalties paid to Protectimmun GmbH, a patent EP 1411977: Composition containing bacterial antigens used for the prophylaxis and the treatment of allergic diseases licensed to Protectimmun GmbH, a patent number EP1637147: Stable dust extract for allergy protection licensed to Protectimmun GmbH, and a patent EP 1994570: Pharmaceutical compound to protect against allergies and inflammatory diseases licensed to Protectimmun GmbH. Matthias V. Kopp reports no conflict of interest, Gesine Hansen reports no conflict of interest. Klaus F. Rabe reports grants and personal fees from Boehringer Ingelheim and Astra Zeneca, personal fees from Novartis, Roche, Chiesi Pharmaceuticals, Regeneron, Sanofi and Berlin Chemie outside the submitted work. Henrik Watz reports no conflict of interest, Frauke Pedersen reports no conflict of interest.

**Author details**

1. LungClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Wohrendamm 80, 22927 Grosshansdorf, Germany.
2. Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
3. Research Center Borstel, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany.
4. Department for Internal Medicine I, Airway Research Center North (ARCN), German Center for Lung Research (DZL), University Hospital Schleswig-Holstein-Kampen, Kiel, Germany.
5. Fraunhofer ITEM, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATHE), German Center for Lung Research, Hannover, Germany.
6. Pulmonary Research Institute at the LungClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany.
7. Department of Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
8. Department of Biomedical Informatics, Heinrich-Lanz-Center, University Medical Center Mannheim, Mannheim, Germany.
9. Dr Von Hauner Children’s Hospital, Ludwig Maximilians University of Munich, Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), Munich, Germany.
10. Department of Pediatric Pulmonology, Inselspital, University Children’s Hospital of Bern, University of Bern, Bern, Switzerland.
11. Division of Pediatric Pneumology and Allergology, University Hospital Schleswig-Holstein-Campus Luebeck, Airway Research...
References
1. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006;368(9537):804–13.
2. Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014;133(6):1557–63.e5.
3. Jatakanon A, Uauy C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1532–9.
4. Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol. 1995;95(4):843–52.
5. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non‑eosinophilic chronic obstructive pulmonary disease. Respir Med. 2015;109(10):1360–2.
6. Lachowicz‑Scroggins ME, Dunican EM, Charbit AR, Raymond W, Looney MR, Peters MC, et al. Extracellular DNA, neutrophil extracellular traps, and inflammation in severe persistent asthma. Front Immunol. 2019;10:976–85.
7. Granger V, Taillé C, Roach D, Letuvé S, Dupin C, Hamidi F, et al. Circulating neutrophil and eosinophil extracellular traps are markers of severe asthma. Allergy. 2020;75:699–702.
8. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DG, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5.
9. Uddin M, Watz H, Malmgren A, Pedersen F. NETopathic inflammation in chronic obstructive pulmonary disease and severe asthma. Front Immunol. 2019;10:47.
10. Saffarzadeh M, Juenemann C, Queisser MA, Lochnit G, Barreto G, et al. Neutrophil extracellular traps increase airway mucus viscoelasticity and mucus hypersecretion in mice. Oncotarget. 2018;9(17):13276–86.
11. Galuska SP , et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS ONE. 2012;7:e32366.
12. Fuchs O, Bahmer T, Weckmann M, Dittrich A‑M, Schaub B, Rösler B, et al. The all age asthma cohort (ALLIANCE)—from early beginnings to chronic disease: a longitudinal cohort study. BMC Pulm Med. 2018;18(1):140.
13. Pedersen F, Marwitz S, Seehase S, Kirsten A‑M, Zabel P, Vollmer E, et al. HOPE‑preservation of paraffin‑embedded sputum samples—a new way of bioprocessing in COPD. Respir Med. 2013;107(4):587–95.
14. Pedersen F, Marwitz S, Holz O, Kirsten A, Bahmer T, Waschki B, et al. Neutrophil extracellular trap formation and extracellular DNA in sputum of stable COPD patients. Respir Med. 2015;109(10):1360–2.
15. Belda J, Leigh R, Parameswaran K, O'Byrne PM, Sears MR, Hargreave FE. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med. 2000;161(2 Pt 1):475–8.